Brand Intelligence Graph
Company Overview
About NewLimit
NewLimit is a longevity biotechnology company that demonstrated the first-ever restoration of youthful killing function in aged human CD8 T cells using transcription factor payloads — a major biological milestone with implications for cancer immunotherapy and immune aging. The company raised $130 million in Series B financing led by Kleiner Perkins, followed by $45 million in additional financing from Eli Lilly at a $1.62 billion valuation, with clinical studies in planning.
Business Model & Competitive Advantage
The T cell rejuvenation approach addresses a fundamental problem in aging immunity: CD8 T cells progressively lose their ability to kill cancer cells and clear infections as humans age, contributing to increased cancer risk and infectious disease vulnerability in older adults. NewLimit's transcription factor approach reprograms these aged cells back toward a youthful functional state without genetic modification, potentially enabling a therapeutic that restores immune function across multiple age-related conditions.
Competitive Landscape 2025–2026
Eli Lilly's direct investment is the most significant institutional signal: Lilly is one of the world's largest pharmaceutical companies with a deep oncology and immunology portfolio, and its $45 million strategic investment indicates active interest in licensing or collaborating on NewLimit's platform for specific disease indications. The $1.62 billion valuation reflects both the technical milestone and the commercial potential Lilly's diligence validated.
Key Differentiators
Emerging Innovator
NewLimit is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare NewLimit with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from NewLimit? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim NewLimit Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention NewLimit vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →